|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UTP11 |
Gene summary for UTP11 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UTP11 | Gene ID | 51118 |
| Gene name | UTP11 small subunit processome component | |
| Gene Alias | CGI-94 | |
| Cytomap | 1p34.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9Y3A2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51118 | UTP11 | HCC1 | Human | Liver | HCC | 4.68e-05 | 3.88e+00 | 0.5336 |
| 51118 | UTP11 | HCC2 | Human | Liver | HCC | 2.69e-25 | 4.58e+00 | 0.5341 |
| 51118 | UTP11 | S014 | Human | Liver | HCC | 4.94e-23 | 7.78e-01 | 0.2254 |
| 51118 | UTP11 | S015 | Human | Liver | HCC | 1.80e-27 | 9.84e-01 | 0.2375 |
| 51118 | UTP11 | S016 | Human | Liver | HCC | 4.99e-32 | 9.05e-01 | 0.2243 |
| 51118 | UTP11 | S027 | Human | Liver | HCC | 9.06e-20 | 1.15e+00 | 0.2446 |
| 51118 | UTP11 | S028 | Human | Liver | HCC | 1.52e-33 | 1.20e+00 | 0.2503 |
| 51118 | UTP11 | S029 | Human | Liver | HCC | 2.04e-36 | 1.54e+00 | 0.2581 |
| 51118 | UTP11 | male-WTA | Human | Thyroid | PTC | 2.31e-25 | 1.47e-01 | 0.1037 |
| 51118 | UTP11 | PTC01 | Human | Thyroid | PTC | 8.63e-08 | 6.50e-02 | 0.1899 |
| 51118 | UTP11 | PTC04 | Human | Thyroid | PTC | 8.14e-08 | 6.77e-02 | 0.1927 |
| 51118 | UTP11 | PTC05 | Human | Thyroid | PTC | 1.21e-06 | 3.02e-01 | 0.2065 |
| 51118 | UTP11 | PTC06 | Human | Thyroid | PTC | 1.90e-16 | 5.41e-01 | 0.2057 |
| 51118 | UTP11 | PTC07 | Human | Thyroid | PTC | 9.52e-25 | 4.06e-01 | 0.2044 |
| 51118 | UTP11 | ATC11 | Human | Thyroid | ATC | 6.39e-05 | 4.76e-01 | 0.3386 |
| 51118 | UTP11 | ATC12 | Human | Thyroid | ATC | 9.51e-08 | 2.19e-01 | 0.34 |
| 51118 | UTP11 | ATC13 | Human | Thyroid | ATC | 7.21e-19 | 3.68e-01 | 0.34 |
| 51118 | UTP11 | ATC2 | Human | Thyroid | ATC | 4.18e-05 | 6.76e-01 | 0.34 |
| 51118 | UTP11 | ATC4 | Human | Thyroid | ATC | 3.67e-08 | 3.41e-01 | 0.34 |
| 51118 | UTP11 | ATC5 | Human | Thyroid | ATC | 5.31e-22 | 4.25e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:002261322 | Liver | HCC | ribonucleoprotein complex biogenesis | 355/7958 | 463/18723 | 7.76e-52 | 4.92e-48 | 355 |
| GO:004225422 | Liver | HCC | ribosome biogenesis | 246/7958 | 299/18723 | 4.99e-46 | 1.58e-42 | 246 |
| GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
| GO:001607212 | Liver | HCC | rRNA metabolic process | 193/7958 | 236/18723 | 1.26e-35 | 1.14e-32 | 193 |
| GO:000636421 | Liver | HCC | rRNA processing | 185/7958 | 225/18723 | 8.14e-35 | 6.45e-32 | 185 |
| GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
| GO:0022613113 | Thyroid | PTC | ribonucleoprotein complex biogenesis | 292/5968 | 463/18723 | 3.24e-44 | 2.05e-40 | 292 |
| GO:0042254113 | Thyroid | PTC | ribosome biogenesis | 202/5968 | 299/18723 | 3.47e-37 | 5.47e-34 | 202 |
| GO:0006364112 | Thyroid | PTC | rRNA processing | 156/5968 | 225/18723 | 5.58e-31 | 5.03e-28 | 156 |
| GO:0016072112 | Thyroid | PTC | rRNA metabolic process | 160/5968 | 236/18723 | 5.68e-30 | 3.58e-27 | 160 |
| GO:003447018 | Thyroid | PTC | ncRNA processing | 215/5968 | 395/18723 | 7.14e-21 | 1.22e-18 | 215 |
| GO:00346608 | Thyroid | PTC | ncRNA metabolic process | 239/5968 | 485/18723 | 5.54e-16 | 4.26e-14 | 239 |
| GO:002261334 | Thyroid | ATC | ribonucleoprotein complex biogenesis | 292/6293 | 463/18723 | 3.05e-39 | 9.63e-36 | 292 |
| GO:004225434 | Thyroid | ATC | ribosome biogenesis | 203/6293 | 299/18723 | 3.63e-34 | 4.59e-31 | 203 |
| GO:000636432 | Thyroid | ATC | rRNA processing | 157/6293 | 225/18723 | 9.02e-29 | 5.70e-26 | 157 |
| GO:001607232 | Thyroid | ATC | rRNA metabolic process | 161/6293 | 236/18723 | 1.02e-27 | 5.89e-25 | 161 |
| GO:003447021 | Thyroid | ATC | ncRNA processing | 216/6293 | 395/18723 | 3.14e-18 | 3.98e-16 | 216 |
| GO:003466021 | Thyroid | ATC | ncRNA metabolic process | 240/6293 | 485/18723 | 2.03e-13 | 9.91e-12 | 240 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UTP11 | SNV | Missense_Mutation | c.74G>A | p.Arg25Gln | p.R25Q | Q9Y3A2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UTP11 | SNV | Missense_Mutation | c.425N>T | p.Thr142Ile | p.T142I | Q9Y3A2 | protein_coding | tolerated(0.11) | possibly_damaging(0.825) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| UTP11 | insertion | Frame_Shift_Ins | novel | c.120_121insGGTA | p.Ala41GlyfsTer4 | p.A41Gfs*4 | Q9Y3A2 | protein_coding | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| UTP11 | insertion | Nonsense_Mutation | novel | c.122_123insGTGGACAGGCGCTAGCGAATAAGAACTGGCTCTTAT | p.Ala41_Asp42insTrpThrGlyAlaSerGluTerGluLeuAlaLeuIle | p.A41_D42insWTGASE*ELALI | Q9Y3A2 | protein_coding | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| UTP11 | SNV | Missense_Mutation | c.454G>A | p.Ala152Thr | p.A152T | Q9Y3A2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| UTP11 | SNV | Missense_Mutation | novel | c.342G>C | p.Lys114Asn | p.K114N | Q9Y3A2 | protein_coding | tolerated(0.14) | possibly_damaging(0.891) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| UTP11 | SNV | Missense_Mutation | novel | c.119N>T | p.Arg40Leu | p.R40L | Q9Y3A2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3858-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| UTP11 | SNV | Missense_Mutation | c.74G>A | p.Arg25Gln | p.R25Q | Q9Y3A2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| UTP11 | SNV | Missense_Mutation | novel | c.184A>T | p.Asn62Tyr | p.N62Y | Q9Y3A2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| UTP11 | SNV | Missense_Mutation | novel | c.569G>T | p.Arg190Leu | p.R190L | Q9Y3A2 | protein_coding | deleterious(0.01) | benign(0.219) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |